Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer

Table 2 Multivariate survival analysis by Cox regressions

	HR and 95%CI				Overall
	HR	Lower	Upper	P value	P value
Adjuvant chemotherapy					0.001
Surgery only	Reference
FOLFOX6	0.762	0.503	1.156	0.201
XELOX	0.564	0.416	0.765	< 0.001
Pathological N category					< 0.001
N0	Reference
N1	1.613	1.049	2.483	0.030
N2	2.952	2.011	4.334	< 0.001
N3a	3.938	2.702	5.739	< 0.001
N3b	5.025	3.382	7.465	< 0.001
Tumor location					0.003
Whole stomach	Reference
Upper	0.671	0.421	1.071	0.094
Middle	0.663	0.414	1.064	0.088
Lower	0.681	0.422	1.099	0.115
Remnant stomach	1.454	0.791	2.675	0.228
Macroscopic Borrmann type					< 0.001
I and II	Reference
III	1.199	0.875	1.642	0.258
IV and V	2.142	1.469	3.124	< 0.001
Pathological T category					< 0.001
T1 and 2
T3	1.112	0.477	2.590	0.806
T4a	3.010	1.574	5.757	0.001
T4b	4.944	2.477	9.870	< 0.001

HR: Hazard ratio; FOLFOX6: 5-fluorouracil, folinic acid and oxaliplatin; XELOX: Capecitabine and oxaliplatin.